Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based specialty pharmaceutical company Valeant Pharmaceuticals International has completed its sale of certain business operations located in western Europe, eastern Europe, and certain export markets to Meda, pursuant to the acquisition agreement previously entered into by Meda and Valeant.
Subscribe to our email newsletter
Valeant has received approximately $425 million in cash from Meda at closing, which is subject to certain closing adjustments.
Goldman, Sachs & Co served as financial advisor to Valeant and Skadden, Arps, Slate, Meagher & Flom provided legal advice.